Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) EBIT Margin (2024 - 2025)

Prime Medicine's EBIT Margin history spans 2 years, with the latest figure at 5800.48% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 377473.0% year-over-year to 5800.48%; the TTM value through Dec 2025 reached 4498.06%, up 228930.0%, while the annual FY2025 figure was 4498.06%, 228930.0% up from the prior year.
  • EBIT Margin reached 5800.48% in Q4 2025 per PRME's latest filing, down from 4405.96% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 2025.74% in Q4 2024 to a low of 25948.33% in Q3 2024.